Summary
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida, a direct-from-blood test that identifies blood stream infections that causes sepsis and candidemia; T2Bacteria, a direct-from-blood test, which detects bacterial pathogens associated with sepsis; T2Resistance to identify carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus. In addition, it is developing T2Biothreat for detection of biothreat pathogens; comprehensive sepsis panel to detect bloodstream infections caused by bacterial and Candida species, and antibiotic resistant markers; T2Cauris to provide direct detection of the emerging superbug Candida auris in patient skin, patient blood, and hospital environmental samples; and T2Lyme, a direct-from-blood test panel designed to run on the T2Dx Instrument to identify the bacteria that cause Lyme disease. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
History
T2 Biosystems was founded in 2006 by co-founders Dr. Jack Phillips, Prof. Cynthia Mullen, and Dr. Ross Johnson. Its rapid diagnostic platform uses a non-culture-based technology that allows for the direct detection of pathogens in as little as four to six hours. Its products include its T2Dx System, which detects sepsis-causing pathogens, as well as its T2Bacteria Panel, T2Candida Panel, T2Bacteria Detection Kit and T2MR Detection Kit.
Mission
T2 Biosystems mission is to provide accurate and actionable diagnostic information to clinicians and patients, speeding up detection and ultimately enabling more effective treatment decisions and patient outcomes.
Vision
T2 Biosystems' vision is to revolutionize healthcare by developing, validating and commercializing innovative diagnostic technologies that enable clinicians to accurately detect, diagnose and treat patients faster and with greater outcome.
Key Team
Mr. John M. Sprague CPA (Chief Financial Officer)
Ms. Kelley J. Morgan (Chief People Officer)
Dr. Aparna Jha Ahuja M.D. (Chief Medical Officer & Chairman of Scientific Advisory Board)
Mr. Brett A. Giffin (Chief Commercial Officer)
Dr. Roger Smith Ph.D. (Sr. VP of Science R&D)
Recognition and Awards
In 2017, T2 Biosystems received the Frost & Sullivan Technology Innovation Award for its T2 Diagnostics Platform and the MassTLC Leadership Award for Life Science Company of the Year.
References
United States 